to have to vie to run for president of the united states again in twenty , insul twenty four . it s insulting. it s sad.tiit s s, it s humiliating and it needs t it s humiliating, and it needsou to end. and like you said, s ai i m wondering where hiss advi advisers are, but mostlyso i m wondering where his family members ar me. . wh where is jill biden saying thies is enough of this is humiliating for my husbanl bm weil need to take a step back av evaluate that. this is elder abuse take and qe frankly, it s repugnant.fr you know,ankl the concern he. listen, people fall older, people fall more . fal they lose motor function as they get older. but that s just kind off an one sign of many as you get older and it s like g they ignorete all the other sigs of aging and tell us that we rei mean for pointing this out. ngtell yeah, again, that s whs frustrating. if he ha fallen i mean, we all fall, we all trip, we and all stumble. right. this isn t jus trid t a one timn thing. this is somet
20.03.2023 - Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced new long-term data for Evrysdi (risdiplam) in a broad range of people aged 2-25 years with spinal muscular atrophy (SMA) from the pivotal SUNFISH study. Data . Seite 1
Taysha Gene Therapies has encouraging data from an open-label, Phase 1/2 study in the rare disease giant axonal neuropathy. It might not be enough. The FDA recommended the biotech conduct a randomized and placebo-controlled study a challenge in any ultra-rare disease.